Copyright © 2001 by the European Society of Cardiology.
Editorials
Hormone replacement therapy: where we stand in Europe
a Fondazione Centro, S. Raffaele Del Monte Tabor, Rome, Italy
b Faculté de Médecine Saint-Antoine, Paris, France
c Universitá degli Studi di Cagliari, Cagliari, Italy
d Hospital Sant Pau, Barcelona, Spain
e Karolinska Hospital, Stockholm, Sweden
f St Mary's Hospital, London, U.K
g University Hospital, Linkoping, Sweden
References
- Vital Statistics of the United States. 1989. Vol II: Morality. Part A. Washington: Government Printing Office; 1993. p. 931101
- Bush TI, Barret-Connor E, Cowan LD. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:11021109
[Abstract/Free Full Text] - Henderson BE, Paganini-Hill A, Ross RK. Decreased moratality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:7578[Abstract]
- Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Med. 1991;20:4763[CrossRef][ISI][Medline]
- Grodstein F, Stampfer MJ, Mason JE. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453461
[Abstract/Free Full Text] - Grady D, Rubin SM, Petitti DB. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:10161037[ISI][Medline]
- Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:7479[ISI][Medline]
- Falkeborn M, Persson I, Adami HO. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement. Br J Obstet Gynecol. 1992;99:821828[ISI][Medline]
- Psaty BM, Heckberr SR, Atkins D. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Int Med. 1994;154:13331339[Abstract]
- Hulley S, Grady D, Bush TA. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc. 1998;280:605618
[Abstract/Free Full Text] - JAMA. 1995;273:199208[Abstract]
- Adams MR, Clarkson TB, Kaplan JR, Koritnik DR. Ovarian secretions and atherosclerosis. Naftolin F, Gutman JN, DeChemey AH. Ovarian secretion and cardiovascular and neurological function. New York: Raven Press; 1990. p. 151159
- Adams MR, Kaplan JR, Manuck SB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 1990;10:10511057
[Abstract/Free Full Text] - Barrett-Connor E, Wenger NK, Grady D. Coronary heart disease in women, randomized trials, HERS and RUTH. Maturitas. 1998;31:17[CrossRef][ISI][Medline]
- Bolla M, Mousseau M, Winkel P. Modulation of indications of adjuvant hormone therapy with tamoxifen in T1T2/N0N1 breast cancers. Preliminary results of a multicentre study with 695 cases. Bull Cancer. 1994;81:10851090[ISI][Medline]
- Tunstall-Pedoe H, Kuulasmaa K, Mahonen M. Contribution of trends in survival and coronary event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA populations. Lancet. 1999;353:15471557[CrossRef][ISI][Medline]
- Keil U, Kuulasmaa K. WHO MONICA Project: risk factors. Int J Epidemiol. 1989;18:S46S55[Abstract]
This article has been cited by other articles:
![]() |
J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Genazzani, W. Feeman Jr, L. Mosca, P. Collins, D. M. Herrington, R. C. Pasternak, R. M. Robertson, K. Schenck-Gustafsson, S. C. Smith Jr, K. A. Taubert, et al. Hormone Replacement Therapy and Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association * Hormone Replacement Therapy and Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association * Response Circulation, March 26, 2002; 105 (12): e71 - e71. [Full Text] [PDF] |
||||
![]() |
S. B. Hulley, V. Bittner, C. Furberg, D. Grady, D. Herrington, E. Vittinghoff, and N. Wenger Hormone treatment--misconceptions and agreements Eur. Heart J., January 1, 2002; 23(1): 89 - 90. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


